ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Investigator: Bincy Abraham, MD

Study Coordinator: Melissa Whipple

Status: Enrolling

ClinicalTrials.gov Number: NCT05507203

Phone: 713.441.3247

Protocol Number: PRO00036506

Description

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials